Drug Profile
Research programme: anti-fibrotic therapeutics - LG Chem
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Antifibrotics
- Mechanism of Action NF-kappa B inhibitors; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pulmonary fibrosis
Most Recent Events
- 27 Sep 2023 Research programme for anti-fibrotic therapeutics is still in preclinical development in Pulmonary-fibrosis in South Korea (LG Chem pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in South Korea
- 03 Sep 2016 Preclinical trials in Pulmonary fibrosis in South Korea (unspecified route)